172 related articles for article (PubMed ID: 35696238)
1. Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in Cancer.
Ferreira MN; Rao M; Kamal AH; Shariff A
J Palliat Med; 2022 Nov; 25(11):1715-1720. PubMed ID: 35696238
[TBL] [Abstract][Full Text] [Related]
2. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
3. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
4. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
5. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
6. Management of Immune-Related Endocrinopathies in Anticancer Treatment with Checkpoint Inhibitors.
Lakomý R; Poprach A; Kazda T
Klin Onkol; 2020; 33(1):15-19. PubMed ID: 32075383
[TBL] [Abstract][Full Text] [Related]
7. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy.
Chiloiro S; Bianchi A; Giampietro A; Milardi D; De Marinis L; Pontecorvi A
Trends Endocrinol Metab; 2022 Feb; 33(2):87-104. PubMed ID: 34895977
[TBL] [Abstract][Full Text] [Related]
8. [Endocrinopathies induced by immune checkpoint inhibitors].
Jaafar J; Mavromati M; Philippe J
Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
10. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
11. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
12. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract][Full Text] [Related]
13. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
14. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R
Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099
[TBL] [Abstract][Full Text] [Related]
16. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
17. Monitoring Endocrine Complications of Immunotherapy: A Screening Tool.
Majety P; Groysman A; Seery V; Shea M; Hou R
Cureus; 2022 Jul; 14(7):e26859. PubMed ID: 35974849
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
20. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
